| pubmed-article:1524911 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1524911 | lifeskim:mentions | umls-concept:C0015967 | lld:lifeskim |
| pubmed-article:1524911 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:1524911 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1524911 | lifeskim:mentions | umls-concept:C1136254 | lld:lifeskim |
| pubmed-article:1524911 | lifeskim:mentions | umls-concept:C1880496 | lld:lifeskim |
| pubmed-article:1524911 | pubmed:issue | 4-5 | lld:pubmed |
| pubmed-article:1524911 | pubmed:dateCreated | 1992-10-19 | lld:pubmed |
| pubmed-article:1524911 | pubmed:abstractText | We evaluated the efficacy of piperacillin-pefloxacin as a non-nephrotoxic antibiotic combination in febrile neutropenic cancer patients treated with nephrotoxic chemotherapy. 40 patients: 34 with solid tumours and 6 with non-Hodgkin lymphoma, were treated during 55 episodes with: piperacillin 4 g intravenously every 8 h and pefloxacin 400 mg intravenously every 12 h. If the patient remained febrile after 72 h, 1 g vancomycin intravenously was added every 12 h. The mean duration of neutropenia was 7 days (range 3-13). Infection was microbiologically documented in 13 episodes (8 gram-positive cocci and 7 gram-negative bacilli). Temperature became normal in 38 patients with piperacillin-pefloxacin and 12 further episodes were resolved by the addition of vancomycin. 2 patients had an early change of antibiotics because of clinical deterioration, there were 2 protocol violations and 1 patient's temperature became normal after the addition of amphotericin. Neither septic death nor toxicity were observed. We conclude that this empirical treatment is active and safe and warrants further comparative trials. | lld:pubmed |
| pubmed-article:1524911 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1524911 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524911 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1524911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1524911 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1524911 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:1524911 | pubmed:author | pubmed-author:DrozJ PJP | lld:pubmed |
| pubmed-article:1524911 | pubmed:author | pubmed-author:AndremontAA | lld:pubmed |
| pubmed-article:1524911 | pubmed:author | pubmed-author:AzabMM | lld:pubmed |
| pubmed-article:1524911 | pubmed:author | pubmed-author:KattanJJ | lld:pubmed |
| pubmed-article:1524911 | pubmed:author | pubmed-author:RibragVV | lld:pubmed |
| pubmed-article:1524911 | pubmed:author | pubmed-author:Boutan-Laroze... | lld:pubmed |
| pubmed-article:1524911 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1524911 | pubmed:volume | 28A | lld:pubmed |
| pubmed-article:1524911 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1524911 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1524911 | pubmed:pagination | 867-70 | lld:pubmed |
| pubmed-article:1524911 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:meshHeading | pubmed-meshheading:1524911-... | lld:pubmed |
| pubmed-article:1524911 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1524911 | pubmed:articleTitle | Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients. | lld:pubmed |
| pubmed-article:1524911 | pubmed:affiliation | Department of Medicine, Institut Gustave-Roussy, Villejuif, France. | lld:pubmed |
| pubmed-article:1524911 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1524911 | pubmed:publicationType | Clinical Trial | lld:pubmed |
